Sign In
Buy IBRX
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026
New York, New York--(Newsfile Corp. - April 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19
NEW YORK, April 19, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and M
New York, New York--(Newsfile Corp. - April 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19
IBRX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
07:22am, Saturday, 18'th Apr 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their Options If you purchased or acqu
NEW ORLEANS, April 17, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a securitie
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
06:46pm, Friday, 17'th Apr 2026
NEW YORK, April 17, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
02:08pm, Friday, 17'th Apr 2026
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. , a top complex litigation law firm, is investigating ImmunityBio Inc. (NASDAQ: IBRX) (“ImmunityBio” or the “Company”) for po
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ImmunityBio (IBRX) To Contact Him Directly To Discuss Their Options
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
11:10am, Friday, 17'th Apr 2026
LOS ANGELES, April 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityB
SAN FRANCISCO, April 17, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBi
Reframing ImmunityBio: The Long-Term Platform Opportunity Beyond Anktiva
07:49am, Friday, 17'th Apr 2026
ImmunityBio is transitioning from a single-product biotech to a potential multi-billion-dollar oncology and cell therapy platform company. Anktiva's commercial momentum is strong, with 1Q26 revenue up
NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and
SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired Immuni
NEW ORLEANS, April 16, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a securi
Did you buy IBRX securities between January 19, 2026, and March 24, 2026? Affected IBRX Investor Summary Who: ImmunityBio, Inc. (NASDAQ: IBRX) What: Securities fraud class action lawsuit filed Class
